Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04386616 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 396
- Enrollment target
NCT04386616 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 396 participants.
The verdict
NCT04386616, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 396 participants
- Enrollment target
Study Summary
This is a Phase II, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of MSTT1041A (astegolimab) compared with placebo and of UTTR1147A compared with placebo, in combination with standard of care (SOC), in patients hospitalized with severe coronavirus disease 2019 (COVID-19) pneumonia.
Interventions
- DRUG MSTT1041A
- DRUG MSTT1041A-matched Placebo
- DRUG UTTR1147A
- DRUG UTTR1147A-matched Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 2020-06-02 |
| Est. Completion | 2021-02-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04386616
The ClinicalTrials.gov registry entry for NCT04386616 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 396 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which MSTT1041A is the first listed.
NCT04386616 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04386616 about?
NCT04386616 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia". This is a Phase II, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of MSTT1041A (astegolimab) compared with placebo and of UTTR1147A compared with placebo, in combination with standard of care (SOC), in patients hospitalized with severe coronavirus ...
What is the current status of trial NCT04386616?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 396 participants. The study started on 2020-06-02. Estimated completion is 2021-02-12.
What interventions are being tested in trial NCT04386616?
The interventions under investigation include: MSTT1041A (DRUG), MSTT1041A-matched Placebo (DRUG), UTTR1147A (DRUG), UTTR1147A-matched Placebo (DRUG).
Who is sponsoring clinical trial NCT04386616?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.